Search results
Results from the WOW.Com Content Network
Statin-associated autoimmune myopathy (SAAM), also known as anti-HMGCR myopathy, is a very rare form of muscle damage caused by the immune system in people who take statin medications. [1] However, there are cases of SAAM in patients who have not taken statin medication, and this can be explained by the exposure to natural sources of statin ...
The muscle damage is most usually caused by a crush injury, strenuous exercise, medications, or a substance use disorder. [3] Other causes include infections , electrical injury , heat stroke , prolonged immobilization, lack of blood flow to a limb , or snake bites [ 3 ] as well as intense or prolonged exercise, particularly in hot conditions ...
Statin-induced rhabdomyolysis is rare, occurring in less than 0.1% of people who take statins. [ 64 ] [ 65 ] [ 66 ] Statin induced rhabdomyolysis, as with other statin associated muscle symptoms, occurs most commonly in the first year of treatment but can occur at any time during treatment. [ 64 ]
[5] [65] Over 5 years of treatment statins result in 75 cases of diabetes, 7.5 cases of bleeding stroke, and 5 cases of muscle damage per 10,000 people treated. [34] This could be due to the statins inhibiting the enzyme (HMG-CoA reductase), which is necessary to make cholesterol, but also for other processes, such as CoQ 10 production, which ...
Statins lower bad cholesterol and thereby decrease the number of fatty deposits in your arteries to prevent plaque buildup that leads to blockages and heart attacks. Antiarrhythmic medications.
The Food and Drug Administration is recommending that physicians restrict prescribing high-dose Simvastatin (Zocor, Merck) to patients, given an increased risk of muscle damage. The FDA drug safety communication stated that physicians should limit using the 80-mg dose unless the patient has already been taking the drug for 12 months and there ...
In other words, as many as 4 million people in the U.S. who currently take statins for primary prevention — meaning they have not had a cardiovascular event such as a stroke or heart attack ...
In other words, evidence from a few studies suggests that GLP-1-agonist-induced weight loss may lead to expected levels of muscle loss while improving muscle quality, but further research is needed.